Eli Lilly and Company (NYSE:LLY) Shares Sold by Transform Wealth LLC

Transform Wealth LLC lowered its stake in Eli Lilly and Company (NYSE:LLY) by 42.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,389 shares of the company’s stock after selling 4,050 shares during the period. Transform Wealth LLC’s holdings in Eli Lilly and Company were worth $4,192,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Truvestments Capital LLC increased its holdings in Eli Lilly and Company by 13.9% in the 3rd quarter. Truvestments Capital LLC now owns 410 shares of the company’s stock worth $220,000 after acquiring an additional 50 shares in the last quarter. Trexquant Investment LP acquired a new position in shares of Eli Lilly and Company during the 3rd quarter worth about $3,874,000. Trustmark National Bank Trust Department boosted its holdings in Eli Lilly and Company by 123.3% in the 3rd quarter. Trustmark National Bank Trust Department now owns 2,302 shares of the company’s stock worth $1,236,000 after buying an additional 1,271 shares during the last quarter. Roundview Capital LLC increased its stake in Eli Lilly and Company by 1.8% during the 3rd quarter. Roundview Capital LLC now owns 2,328 shares of the company’s stock worth $1,250,000 after buying an additional 41 shares in the last quarter. Finally, Private Advisory Group LLC raised its holdings in shares of Eli Lilly and Company by 6.3% during the third quarter. Private Advisory Group LLC now owns 16,788 shares of the company’s stock valued at $9,018,000 after acquiring an additional 988 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 17,229 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $902.38, for a total value of $15,547,105.02. Following the sale, the insider now owns 97,556,910 shares of the company’s stock, valued at $88,033,404,445.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, major shareholder Lilly Endowment Inc sold 17,229 shares of the stock in a transaction on Monday, June 24th. The stock was sold at an average price of $902.38, for a total transaction of $15,547,105.02. Following the sale, the insider now owns 97,556,910 shares of the company’s stock, valued at $88,033,404,445.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. Insiders sold 789,704 shares of company stock valued at $672,385,964 in the last 90 days. 0.13% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

LLY has been the subject of several research reports. Argus upped their price objective on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. The Goldman Sachs Group boosted their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. Citigroup raised their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. Finally, TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $812.72.

Eli Lilly and Company Stock Up 0.1 %

Shares of Eli Lilly and Company stock traded up $0.66 during trading hours on Friday, hitting $909.70. The company had a trading volume of 887,296 shares, compared to its average volume of 2,917,085. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The company’s 50-day moving average is $807.55 and its two-hundred day moving average is $735.35. The company has a market cap of $864.59 billion, a P/E ratio of 134.57, a price-to-earnings-growth ratio of 1.97 and a beta of 0.36. Eli Lilly and Company has a twelve month low of $434.34 and a twelve month high of $915.54.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same quarter in the previous year, the company posted $1.62 earnings per share. The firm’s revenue was up 26.0% compared to the same quarter last year. Analysts anticipate that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.57%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.